Randolf A Widder1,2, Thomas S Dietlein3, Sven Dinslage4, Pia Kühnrich5, Corinna Rennings5, Gernot Rössler5,6. 1. Department of Ophthalmology, St. Martinus-Krankenhaus Düsseldorf, Gladbacher Str. 26, D-40219, Düsseldorf, Germany. r.widder@martinus-duesseldorf.de. 2. Department of Ophthalmology, University of Cologne, Cologne, Germany. r.widder@martinus-duesseldorf.de. 3. Department of Ophthalmology, University of Cologne, Cologne, Germany. 4. Augenzentrum Tölzer Land, Bad Tölz, Germany. 5. Department of Ophthalmology, St. Martinus-Krankenhaus Düsseldorf, Gladbacher Str. 26, D-40219, Düsseldorf, Germany. 6. Department of Ophthalmology, RWTH Aachen, Aachen, Germany.
Abstract
PURPOSE: The XEN45 Gel Stent is a flexible hydrophilic tube placed under the conjunctiva via the anterior chamber. This study investigates the IOP (intraocular pressure)-lowering potential, the risk profile, and the success rate of the XEN45 Gel Stent. METHODS: Two hundred and sixty-one eyes underwent surgery. The mean follow-up time was 8.5 months. The aim of the treatment was to achieve adequate IOP reduction without medication. Therefore, all patients who did not show sufficiently reduced IOP underwent a surgical revision with opening of the conjunctiva. To determinate the success rate, we carried out two kinds of analysis: 1) the primary success rate: eyes with appropiate IOP control without medication or surgical revision, and 2) overall success rate: one surgical revision was allowed. RESULTS: Intraocular pressure was lowered from 24.3 mmHg (SD 6.6) to 16.8 mmHg (SD 7.6), and the medication score was lowered from 2.6 (SD 1.1) to 0.2 (SD 0.7). Revisional surgery was performed in 80 eyes (34%). After a first revision, intraocular pressure was lowered to 14.0 mmHg (SD 5.1), and the medication score was lowered to 0.2 (SD 0.6). The primary success rate was 66% and the overall success rate 90%. The primary success rate was higher in pseudophakic eyes (73%) than in phakic eyes (53%) or combined surgery (55%). CONCLUSIONS: We conclude from our data that the XEN45 Gel Stent has an IOP-lowering potential and few side-effects. Pseudophakic eyes seem to have a better primary prognosis compared to combined surgery or surgery in phakic eyes.
PURPOSE: The XEN45 Gel Stent is a flexible hydrophilic tube placed under the conjunctiva via the anterior chamber. This study investigates the IOP (intraocular pressure)-lowering potential, the risk profile, and the success rate of the XEN45 Gel Stent. METHODS: Two hundred and sixty-one eyes underwent surgery. The mean follow-up time was 8.5 months. The aim of the treatment was to achieve adequate IOP reduction without medication. Therefore, all patients who did not show sufficiently reduced IOP underwent a surgical revision with opening of the conjunctiva. To determinate the success rate, we carried out two kinds of analysis: 1) the primary success rate: eyes with appropiate IOP control without medication or surgical revision, and 2) overall success rate: one surgical revision was allowed. RESULTS: Intraocular pressure was lowered from 24.3 mmHg (SD 6.6) to 16.8 mmHg (SD 7.6), and the medication score was lowered from 2.6 (SD 1.1) to 0.2 (SD 0.7). Revisional surgery was performed in 80 eyes (34%). After a first revision, intraocular pressure was lowered to 14.0 mmHg (SD 5.1), and the medication score was lowered to 0.2 (SD 0.6). The primary success rate was 66% and the overall success rate 90%. The primary success rate was higher in pseudophakic eyes (73%) than in phakic eyes (53%) or combined surgery (55%). CONCLUSIONS: We conclude from our data that the XEN45 Gel Stent has an IOP-lowering potential and few side-effects. Pseudophakic eyes seem to have a better primary prognosis compared to combined surgery or surgery in phakic eyes.
Entities:
Keywords:
Filtering surgery; Glaucoma surgery; Migs; XEN Gel Stent
Authors: Arsham Sheybani; Markus Lenzhofer; Melchior Hohensinn; Herbert Reitsamer; Iqbal Ike K Ahmed Journal: J Cataract Refract Surg Date: 2015-10-23 Impact factor: 3.351
Authors: V T Pérez-Torregrosa; Á Olate-Pérez; M Cerdà-Ibáñez; A Gargallo-Benedicto; V Osorio-Alayo; A Barreiro-Rego; A Duch-Samper Journal: Arch Soc Esp Oftalmol Date: 2016-03-16
Authors: Steven J Gedde; Leon W Herndon; James D Brandt; Donald L Budenz; William J Feuer; Joyce C Schiffman Journal: Am J Ophthalmol Date: 2012-01-14 Impact factor: 5.258
Authors: James F Kirwan; Alastair J Lockwood; Peter Shah; Alex Macleod; David C Broadway; Anthony J King; Andrew I McNaught; Pavi Agrawal Journal: Ophthalmology Date: 2013-09-23 Impact factor: 12.079
Authors: Michael M Lin; William H Morgan; Natasha N Kolomeyer; Stephen J Moster; Cindy X Zheng; Antonio Giubilato; Marlene R Moster Journal: J Glaucoma Date: 2019-12 Impact factor: 2.503